Fondazione ICONA
Fondazione ICONA
Fondazione ICONA
Area riservataArea riservata
CRF icona.orgCRF icona.org
ContattiContatti

Publications

La raccolta di tutte le pubblicazioni di Fondazione ICONA,...

La raccolta di tutte le pubblicazioni di Fondazione ICONA, suddivise in Scientific Journals, Congressi, ART Cohort Collaboration, CASCADE, CHAIN, COHERE, D:A:D, EuroCoord, RESPOND ed Altre collaborazioni
La raccolta di tutte le pubblicazioni di Fondazione ICONA, suddivise in Scientific Journals, Congressi, ART Cohort Collaboration, CASCADE, CHAIN, COHERE, D:A:D, EuroCoord, RESPOND ed Altre collaborazioni
La raccolta di tutte le pubblicazioni di Fondazione ICONA, suddivise in Scientific Journals, Congressi, ART Cohort Collaboration, CASCADE, CHAIN, COHERE, D:A:D, EuroCoord, RESPOND ed Altre collaborazioni
La raccolta di tutte le pubblicazioni di Fondazione ICONA, suddivise in Scientific Journals, Congressi, ART Cohort Collaboration, CASCADE, CHAIN, COHERE, D:A:D, EuroCoord, RESPOND ed Altre collaborazioni
La raccolta di tutte le pubblicazioni di Fondazione ICONA, suddivise in Scientific Journals, Congressi, ART Cohort Collaboration, CASCADE, CHAIN, COHERE, D:A:D, EuroCoord, RESPOND ed Altre collaborazioni
La raccolta di tutte le pubblicazioni di Fondazione ICONA, suddivise in Scientific Journals, Congressi, ART Cohort Collaboration, CASCADE, CHAIN, COHERE, D:A:D, EuroCoord, RESPOND ed Altre collaborazioni
La raccolta di tutte le pubblicazioni di Fondazione ICONA, suddivise in Scientific Journals, Congressi, ART Cohort Collaboration, CASCADE, CHAIN, COHERE, D:A:D, EuroCoord, RESPOND ed Altre collaborazioni
La raccolta di tutte le pubblicazioni di Fondazione ICONA, suddivise in Scientific Journals, Congressi, ART Cohort Collaboration, CASCADE, CHAIN, COHERE, D:A:D, EuroCoord, RESPOND ed Altre collaborazioni
La raccolta di tutte le pubblicazioni di Fondazione ICONA, suddivise in Scientific Journals, Congressi, ART Cohort Collaboration, CASCADE, CHAIN, COHERE, D:A:D, EuroCoord, RESPOND ed Altre collaborazioni

Reset della ricerca

Scientific Journals

2024
  1. A d'Arminio Monforte, A Tavelli, A Di Biagio, L Sarmati, G Marchetti; F Bai, A Cingolani, E Quiros-Roldan,C Mussini, M Lichtner, A Vergori, S Piconi, G Orofino, F Fusco, A Bandera, S Nozza, A Castagna, A Antinori Long-term outcomes of bictegravir-emtricitabine-tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort  JAC-2023-1421.R1
2023
  1. A Giacomelli, R Gagliardini, A Tavelli, S De Benedittis, V Mazzotta, G Rizzardini, A Mondi, M Augello, S Antinori, A Vergori, A Gori, M Menozzi, L Taramasso, F M Fusco, A De Vito, g Mancarella, G Marchetti, A d'Arminio Monforte, A Antinori, A Cozzi-Lepri, COVID-19 ICONA study group Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from the Icona network Int J Infect Dis. 2023 Sep 21;S1201-9712(23)00728-2. doi: 10.1016/j.ijid.2023.09.015.
  2. A d'Arminio Monforte, A Tavelli, M Sala, A Mondi, S Rusconi, S Antinori, M Puoti, B M Celesia, L Taramasso, A Saracino, A Antinori, A Cozzi-Lepri on behalf of ICONA Foundation Study Group Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study Journal of Antimicrobial Chemotherapy, dkad026
  3. A d'Arminio Monforte, A Tavelli, R Rossotti, R Gagliardini, A Saracino, S Lo Caputo, E Quiros-Roldan, C Mussini, E Girardi, A Cozzi-Lepri, A Antinori, M Puoti, for the NoCo Study of the Icona cohort Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort Liver International
  4. S Piconi, M Bottanelli, G Marchetti, A Gori, A Castagna, N Squillace, S Cicalini, G Orofino, F Ceccherini-Silberstein, A Di Biagio, A d'Arminio Monforte, A Cozzi-Lepri for Icona Foundation Study Cohort Is HDL-C Plasma Concentration a Possible Marker of HIV Replication? A Retrospective Cross-Sectional Analysis in Untreated HIV-Infected Individuals Accessing HIV Care inItaly. Data from The ICONA Foundation Study Cohort fortune journals
  5. A Vergori, A Tavelli, G Matusali, A M Azzini, M Augello, V Mazzotta, G F Pellicanò, A Costantini, A Cascio, A De Vito, L Marconi, E Righi, A Sartor, C Pinnetti, F Maggi, F Bai, S Lanini, S Piconi, G L Hara, G Marchetti, M Giannella, E Tacconelli, A d'Arminio Monforte, A Antinori, A Cozzi-Lepri and on behalf of the Vax-ICONA-ORECHESTRA Study SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio Vaccines 2023, 11(11), 1664; https://doi.org/10.3390/vaccines11111664
  6. R Gagliardini, A Tavelli, S Rusconi, S Lo Caputo, V Spagnuolo, M Mercedes Santoro, A Costantini, A Vergori, F Maggiolo, A Giacomelli, G Burastero, G Madeddu, E Quiros Roldan, A d'Arminio Monforte, A Antinori, A Cozzi-Lepri, ICONA Foundation Study Group Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort International Journal of Antimicrobial Agents
  7. A d'Arminio Monforte, A Tavelli, R Salpini, L Piermatteo, S D'Anna, S Carrara, V Malagnino, V Mazzotta, G Brancaccio, G C Marchetti, E Rosselli Del Turco, R Rossotti, C Mussini, A Antinori, S Lo Caputo, F Ceccherini Silberstein, G B Gaeta, V Svicher, M Puoti for the Icona Foundation Study Group Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort DOI: 10.1111/liv.15804
2022
  1. Cingolani A, Tavelli A, Calvino GV, Maggiolo F, Girardi E, Cozzi-Lepri A, Perziano A, Meli P, Camposeragna A, Mattioli S, Calzavara D, Gagliardini R, Nozza S, Antinori A, d'Arminio Monforte A; for ICONA Foundation Study Group Awareness and perception of accuracy of the Undetectable=Untransmittable message (U=U) in Italy: results from a survey among PLWHA, infectious-diseases physicians and people having unprotected sex. AIDS Care. 2022 May 17:1-11. doi: 10.1080/09540121.2022.2074960. Online ahead of print.PMID: 35579404
  2. A Cingolani, A Tavelli, F Maggiolo, A Perziano, A Saracino, F Vichi, M Cernuschi, G Guaraldi, E Quiros-Roldan, A Castagna, A Antinori, A d’Arminio Monforte, Icona Foundation Study Group Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy J. Clin. Med. 2022, 11, 471.
  3. P Rodari, F Tamarozzi, S Tais, M Degani, F Perandin, D Buonfrate, E Nicastri, L Lepore, ML Giancola, S Carrara, A Tavelli, A Cozzi-Lepri, A d'Arminio Monforte, R Silva, A Angheben Prevalence of Chagas disease and strongyloidiasis among HIV-infected Latin American immigrants in Italy - The CHILI study Travel Med Infect Dis. 2022 Apr 1;48:102324. doi: 10.1016/j.tmaid.2022.102324
  4. G Brancaccio, M Shanyinde, M Puoti, GB Gaeta, A d'Arminio Monforte, A Vergori, S Rusconi, A Mazzarelli, A Castagna, A Antinori, A Cozzi-Lepri; ICONA Foundation Cohort Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy Pathog Glob Health. 2022 Mar 7:1-9. doi: 10.1080/20477724.2022.2047551
  5. E Girardi, Y Caro-Vega, A Cozzi-Lepri, J Musaazi, G Carriquiry, B Castelnuovo, A Gori, Y C Manabe, J E Gotuzzo, A d'Arminio Monforte, B Crabtree-Ramirez, C Mussini The contribution of late HIV diagnosis on the occurrence of HIV-associated tuberculosis: a 5-year estimate using real-world data AIDS. 2022 Jul 15. doi: 10.1097/QAD.0000000000003321
  6. Gagliardini R, Lorenzini P, Cozzi-Lepri A, Tavelli A, Borghi V, Galli L, Tagliaferri G, Maggiolo F, Mussini C, Castagna A, Monforte AD, Antinori A; Icona Foundation Study Group Real world efficacy of dolutegravir plus lamivudine in PLWH with undetectable viral load after previous failures. J Glob Antimicrob Resist. 2022 Nov 16:S2213-7165(22)00256-9. doi: 10.1016/j.jgar.2022.11.010. Online ahead of print.PMID: 36402369
2021
  1. S Nozza, L Timelli , A Saracino, N Gianotti, C Lazzaretti, A Tavelli, M Puoti, S Lo Caputo, A Antinori, A d'Arminio Monforte, C Mussini, E Girardi Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008-2018 in Italy J Clin Med. 2021 Jul 30;10(15):3391. doi: 10.3390/jcm10153391
  2. R Gagliardini, N Gianotti, F Maggiolo, A Cozzi-Lepri, A Antinori, S Nozza, G Lapadula, A De Luca, C Mussini, A Gori, A Saracino, M Andreoni, A d'Arminio Monforte Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy Int J Antimicrob Agents. 2021 Jul 19:106406. doi: 10.1016/j.ijantimicag.2021.106406. Online ahead of print. PMID: 34293454
  3. M Spaziante, G Taliani, G Marchetti, A Tavelli, M Lichtner, A Cingolani, S Cicalini, E Biliotti, E Girardi, A Antinori, M Puoti, A d'Arminio Monforte, A Cozzi-Lepri Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study Viruses. 2021 Jul 19;13(7):1402. doi: 10.3390/v13071402
  4. E Merlini, A Cozzi-Lepri, A Castagna, A Costantini, S Lo Caputo, S Carrara, E Quiros Roldan, M Ursitti, A Antinori, A d'Arminio Monforte, G Marchetti Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV BMC Infect Dis. 2021 Jun 12; 21(1):557. doi: 10.1186/s12879-021-06260-y
  5. C Mussini, P Lorenzini, A Cozzi-Lepri, A Mammone, G Guaraldi, G Marchetti, M Lichtner, G Lapadula, S Lo Caputo, A Antinori, A d'Arminio Monforte, E Girardi Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss Sci Rep. 2021 May 5; 11(1):9632. doi: 10.1038/s41598-021-88367-5.
  6. A Giacomelli, A Cozzi-Lepri, A Cingolani, A Tavelli, V Mazzotta, D Tesoro, M Bassetti, A Castagna, A Di Biagio, M Lichtner, A d'Arminio Monforte, S Rusconi Does syphilis increase the risk of HIV-RNA elevation >200 copies/mL in HIV positive patients under effective antiretroviral treatment? Data from the ICONA cohort J Acquir Immune Defic Syndr. 2021 Jun 15. doi: 10.1097/QAI.0000000000002749
  7. A Bandera, P Lorenzini, L Taramasso, A Cozzi-Lepri, G Lapadula, C Mussini, A Saracino, F Ceccherini-Silberstein, M Puoti, E Quiros-Roldan, F Montagnani, A Antinori, A d'Arminio Monforte, A Gori The impact of DAA-mediated HCV eradication on CD4(+) and CD8(+) T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort J Viral Hepat. 2021 May;28(5):779-786. doi: 10.1111/jvh.13488. Epub 2021 Mar 11.PMID: 33600068
  8. G Madeddu, A De Vito, A Cozzi-Lepri, A Cingolani , F Maggiolo, CF Perno, R Gagliardini , G Marchetti, A Saracino, A d' Arminio Monforte, A Antinori, E Girardi Time spent with viral load 200 copies/mL in a cohort of people with HIV seen for care in Italy during the U=U prevention campaign era AIDS. 2021 Jan 29. doi: 10.1097/QAD.0000000000002825. Online ahead of print.PMID: 33534204
2020
  1. V Malagnino, C Cerva, A Cingolani, F Ceccherini-Silberstein, A Vergori, G Cuomo, CF Perno, M Puoti, A d'Arminio Monforte, A Cozzi-Lepri, M Andreoni, L Sarmati HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients Open Forum Infect Dis. 2020 Nov 18;8(1):ofaa566. doi: 10.1093/ofid/ofaa566. eCollection 2021 Jan.PMID: 33447635
  2. A Vergori, R Gagliardini, N Gianotti, A Gori, M Lichtner, A Saracino, A De Vito, A Cascio, A Di Biagio, A d'Arminio Monforte, A Antinori, A Cozzi-Lepri Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected individuals with viral load <= 50 copies/ml: does eGFR matter? Int J Antimicrob Agents. 2020 Sep 9:106154. doi: 10.1016/j.ijantimicag.2020.106154
  3. E M Lori, A Cozzi-Lepri, A Tavelli, V Mercurio, S V Ibba, S Lo Caputo, F Castelli, A Castagna, A Gori, G Marchetti, C Venditti, M Clerici, A d'Arminio Monforte, M Biasin Evaluation of the effect of protective genetic variants on cART success in HIV - 1 - infected patients. J Biol Regul Homeost Agents. 2020 Aug 4;34(4). doi: 10.23812/19-527-L
  4. L Fabeni, MM Santoro, P Lorenzini, S Rusconi, N Gianotti, A Costantini, L Sarmati, A Antinori, F Ceccherini-Silberstein, A d'Arminio Monforte, A Saracino, E Girardi Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy Viruses. 2020 Jul 23;12(8):791. doi: 10.3390/v12080791.PMID: 32718024
  5. A d'Arminio Monforte, A Tavelli, A Cozzi-Lepri, A Castagna, S Passerini, D Francisci, A Saracino, F Maggiolo, G Lapadula, E Girardi, CF Perno, A Antinori Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort J Antimicrob Chemother. 2020 Mar 1;75(3):681-689. doi: 10.1093/jac/dkz512.PMID: 31865395
  6. R Rossotti, A Tavelli, S Bonora, A Cingolani, S Lo Caputo, A Saracino, A Soria, L Marinaro, C Uberti-Foppa, C Mussini, M Puoti, A d'Arminio Monforte Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts  Dig Liver Dis. 2020 Apr;52(4):447-451. doi: 10.1016/j.dld.2019.12.007. Epub 2020 Jan 17.PMID: 31959479
2019
  1. S Leone, P Lorenzini, A Cozzi-Lepri, G Orofino, D Bernacchia, A Castagna, M Menozzi, G Guaraldi, G Madeddu, A Di Biagio, M Puoti, A Gori, A d'Arminio Monforte; ICONA Foundation Study Group. Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study.  Eur J Clin Microbiol Infect Dis. 2019 Oct;38(10):1857-1865. doi: 10.1007/s10096-019-03618-8. Epub 2019 Jun 22.
  2. L Taramasso, P Lorenzini, A Di Biagio, M Lichtner, G Marchetti, R Rossotti, G Lapadula, A Cozzi-Lepri, F Vichi, A Antinori, S Bonora, A d'Arminio Monforte; ICONA Foundation Study Group. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort.  J Antimicrob Chemother. 2019 Nov 1;74(11):3295-3304. doi: 10.1093/jac/dkz353.
  3. M Shanyinde, E Girardi, M Puoti, A De Luca, L Sighinolfi, UF Caterina, P Caramello, FC Lampe, A d’Arminio Monforte, A Cozzi-Lepri; ICONA Foundation Study Group. Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? BMC Public Health. 2019 Oct 15;19(1):1291. doi: 10.1186/s12889-019-7608-1.
  4. D Armenia, D Di Carlo, A Cozzi-Lepri, A Calcagno, V Borghi, C Gori, A Bertoli, W Gennari, R Bellagamba, A Castagna, A Latini, C Pinnetti, S Cicalini, A Saracino, G Lapadula, S Rusconi, F Castelli, S Di Giambenedetto, M Andreoni, G Di Perri, A Antinori, C Mussini, F Ceccherini-Silberstein, A d’Arminio Monforte, CF Perno, MM Santoro; ICONA Foundation Study Group. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen.  Antivir Ther. 2019 Apr 12. doi: 10.3851/IMP3309. [Epub ahead of print].
  5. S Rusconi, MM Santoro, N Gianotti, A Antinori, S Bonora, A Cingolani, F Ceccherini-Silberstein, A Tavelli, A d’Arminio Monforte, A Cozzi-Lepri for the ICONA Foundation Study Group. Is the rate of virological failure to cART continuing to decline in recent calendar years?  Journal of Clinical Virology, Volume 116, July 2019, Pages 23-28
  6. N Gianotti, P Lorenzini, A Cozzi-Lepri, a De Luca, G Madeddu, L Sighinolfi, C Pinnetti, C Santoro, P Meraviglia, C Mussini, A Antinori, A d'Arminio Monforte; ICONA Foundation Study Group. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. Antimicrob Chemother. 2019 Jun 7. pii: dkz237. doi: 10.1093/jac/dkz237. [Epub ahead of print]
  7. A d'Arminio Monforte, A Cozzi-Lepri, A Di Biagio,G Marchetti, S Lo Caputo, S Rusconi, N Gianotti, V Mazzotta, G Mazzarello, A Costantini, A Castagna, A Antinori; ICONA Foundation Study Group. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. J Antimicrob Chemother. 2019 Jan 29. doi: 10.1093/jac/dky566. [Epub ahead of print.
  8. A Mondi , A Cozzi-Lepri, A Tavelli, S Rusconi, F Vichi, F Ceccherini-Silberstein, A Calcagno, A De Luca, F Maggiolo, G Marchetti, A Antinori, A d’Arminio Monforte and on behalf of Icona Foundation Study Group. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.  Journal of the International AIDS Society 2019, 22:e25227
  9. A d'Arminio Monforte, A Tavelli, A Cozzi-Lepri, A Castagna, S Passerini, D Francisci, A Saracino, F Maggiolo, G Lapadula, E Girardi, CF Perno, A Antinori for the ICONA Foundation Study Group. Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort. J Antimicrob Chemother. 2019 Dec 22. pii: dkz512. doi: 10.1093/jac/dkz512
2018
  1. A d'Arminio Monforte, H Diaz-Cuervo, A De Luca, F Maggiolo, A Cingolani, S Bonora, A Castagna, E Girardi, A Antinori, S Lo Caputo, G Guaraldi, A Cozzi-Lepri; ICONA Foundation Study Group. Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014.  HIV Med. 2018 Nov 21. doi: 10.1111/hiv.12683. [Epub ahead of print]
  2. C Dentone, A Di Biagio, A Cozzi-Lepri, D Fenoglio, G Filaci, M Lichtner, S Carrara, A Giacometti, L Sighinolfi, G Marchetti, A Antinori, A d'Arminio Monforte; ICONA Foundation Study Group. Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients.  HIV Clin Trials. 2018 Nov 13:1-5. doi: 10.1080/15284336.2018.1488453. [Epub ahead of print]
  3. F Ceccherini-Silberstein, A Cozzi Lepri, C Alteri, E Merlini, M Surdo, G Marchetti, MR Capobianchi, A De Luca, N Gianotti, P Viale, M Andreoni, A Antinori, CF Perno, A d'Arminio Monforte; ICONA Foundation Study Group. Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART.  J Antimicrob Chemother. 2018 Sep 20. doi: 10.1093/jac/dky350. [Epub ahead of print]
  4. M Franzetti, A De Luca, F Ceccherini-Silberstein, V Spagnuolo, E Nicastri, C Mussini, A Antinori, L Monno, J Vecchiet, I Fanti, A d'Arminio Monforte, C Balotta; ICONA Foundation Study Group. Evolution of HIV-1 transmitted drug resistance in Italy in the 2007-2014 period: A weighted analysis.  J Clin Virol. 2018 Sep;106:49-52. doi: 10.1016/j.jcv.2018.07.009. Epub 2018 Jul 26
  5. A Saracino, M Zaccarelli, P Lorenzini, A Bandera, G Marchetti, F Castelli, A Gori, E Girardi, C Mussini, P Bonfanti, A Ammassari, A d'Arminio Monforte; Icona Foundation Study Group. Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy.  BMC Public Health. 2018 Jul 13;18(1):870. doi: 10.1186/s12889-018-5804-z.
  6. L Taramasso, A Di Biagio, F Maggiolo, A Tavelli, S Lo Caputo, S Bonora, M Zaccarelli, P Caramello, A Costantini, C Viscoli, A d’Arminio Monforte and A Cozzi-Lepri on behalf of the Italian Cohort Naive Antiretrovirals (ICONA) Foundation Study Group. First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison.  DOI: 10.1111/hiv.12628,2018 British HIV Association HIV Medicine (2018)
  7. C Mussini, P Lorenzini, A Cozzi-Lepri, G Marchetti, S Rusconi, A Gori, S Nozza, M Lichtner, A Antinori, A Cossarizza, A d’Arminio Monforte and for the Icona Foundation Study Group. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Medicine (2018) 16:79 https://doi.org/10.1186/s12916-018-1046-2
  8. A d'Arminio Monforte, P Lorenzini, A Cozzi-Lepri3, C Mussini, A Castagna5, F Baldelli, M Puoti, F Vichi, A Maddaloni, S Lo Caputo, Nicola Gianotti, A Antinori on behalf of the Icona Foundation Study Group. Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort.  HIV Clin Trials. 2018 Apr;19(2):52-60. doi: 10.1080/15284336.2018.1440691. Epub 2018 Mar 1.
  9. A Saracino, A Cozzi-Lepri, M Shanyinde, F Ceccherini Silberstein, S Nozza, A Di Biagio, G Cassola, G Bruno, M Capobianchi, M Puoti, L Monno, A d'Arminio Monforte; ICONA Foundation Study. HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients.  PLoS One. 2018 Jan 11;13(1):e0190302. doi: 10.1371/journal.pone.0190302. eCollection 2018.
  10. S Leone, M Shanyinde, A Cozzi Lepri, FC Lampe, P Caramello, A Costantini, A Giacometti, A De Luca, A Cingolani, F Ceccherini Silberstein, M Puoti M, A Gori, A d'Arminio Monforte; ICONA Foundation Cohort Study. Incidence and predictors of single drug discontinuation according to the presence of HCVcoinfection in HIV patients from the ICONA Foundation Cohort Study.  Eur J Clin Microbiol Infect Dis. 2018 Jan 9. doi: 10.1007/s10096-017-3180-8. [Epub ahead of print]
2017
  1. M Smit, R Cassidy, A Cozzi-Lepri, E Quiros-Roldan, E Girardi, A Mammone, A Antinori, A Saracino, F Bai, S Rusconi, G Magnani, F Castelli, P Hsue, A d'Arminio Monforte, TB Hallett. Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study. PLoS One. 2017 Oct 23;12(10):e0186638. doi: 10.1371/journal.pone.0186638. eCollection 2017.
  2. N Gianotti, G Marchetti, A Antinori, A Saracino, A Gori, G Rizzardini, M Lichtner, A Bandera, C Mussini, E Girardi, A d’Arminio Monforte, A Cozzi-Lepri; ICONA Foundation Study Group. Brief Report: Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression. J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):417-422. doi: 10.1097/QAI.0000000000001522
  3. B Rossetti, F Bai, A Tavelli, M Galli, A Antinori, F Castelli, G Pellizzer, A Cozzi-Lepri, S Bonora, A d’Arminio Monforte, M Puoti, A De Luca; ICONA Foundation study group. Evolution of the prevalence of HCV infection and HCV genotype distribution in HIV-infected patients in Italy between 1997 and 2015. Clin Microbiol Infect. 2017 Jul 29. pii: S1198-743X(17)30405-6. doi: 10.1016/j.cmi.2017.07.021. [Epub ahead of print]
  4. A De Luca, P Lorenzini, A Castagna, M Puoti, N Gianotti, F Castelli, C Mastroianni, F Maggiolo, A Antinori, G Guaraldi, M Lichtner, A dʼArminio Monforte; ICONA Foundation Study. Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):465-471. doi: 10.1097/QAI.0000000000001443.
  5. N Gianotti, A Cozzi-Lepri, A Antinori, A Castagna, A De Luca, BM Celesia, M Galli, C Mussini, C Pinnetti, V Spagnuolo, A d'Arminio Monforte, F Ceccherini-Silberstein, M Andreoni; Icona Foundation Study and mono-PI/r database Study Cohorts. Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.  PLoS One. 2017 Feb 13;12(2):e0171611. doi: 10.1371/journal.pone.0171611. eCollection 2017.
  6. A d'Arminio Monforte , A Cozzi-Lepri, F Ceccherini-Silberstein, A De Luca, S Lo Caputo, A Castagna, C Mussini, A Cingolani, A Tavelli, M Shanyinde, A Gori, E Girardi, M Andreoni, A Antinori, M Puoti; Icona Foundation and HepaIcona Study Group. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.  PLoS One. 2017 May 17;12(5):e0177402. doi: 10.1371/journal.pone.0177402. eCollection 2017.
  7. M Puoti, P Lorenzini , A Cozzi-Lepri, A Gori, C Mastroianni, G Rizzardini, G Mazzarello, A Antinori , A d'Arminio Monforte, E Girardi, The Icona Foundation Study Group. Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus.  Clinical Microbiology and Infection 23 (2017) 267.e1e267.e4
  8. G Madeddu; S Rusconi; A Cozzi-Lepri; S Di Giambenedetto; S Bonora; A Carbone; A De Luca; N Gianotti; A Di Biagio; A Antinori for the Icona Foundation Study Group. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.  Infection (2017). 5 maggio 2017 - doi:10.1007/s15010-017-1018-z.
  9. S Vita, M Lichtner, G Marchetti, C Mascia, E Merlini, P Cicconi, V Vullo, P Viale, A Costantini, A dʼArminio Monforte; ICONA Foundation Study Group. Soluble CD163 in CMV Infected and Uninfected subjects on Virologically-Suppressive Antiretroviral therapy in the ICONA cohort.  J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):347-352. doi: 10.1097/QAI.0000000000001232.
  10. Cingolani A, Cozzi Lepri A, Teofili L, Galli L, Mazzotta V, Baldin GM, Hohaus S, Bandera A, Alba L, Galizzi N, Castagna A, D'arminio Monforte A, Antinori A; ICONA Foundation Study group. Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. PLoS One. 2017 Oct 31;12(10):e0186549. doi: 10.1371/journal.pone.0186549.
  11. Di Biagio A, Lorenzini P, Gustinetti G, Rusconi S, De Luca A, Lapadula G, Lo Caputo S, Cicalini S, Castelli F, Marchetti G, Antinori A, Monforte AD. Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation.  AIDS Patient Care STDS. 2017 Dec;31(12):487-494. doi: 10.1089/apc.2017.0140.
  12. Nozza S, Cozzi-Lepri A, Bai F, Rusconi S, Gori A, Cinque P, Ammassari A, Caramello P, Tambussi G, D'Arminio Monforte A, Marchetti G; Icona Foundation Study Group. Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort.  PLoS One. 2017 Dec 5;12(12):e0189045. doi: 10.1371/journal.pone.0189045.
2016
  1. S Costarelli, A Cozzi-Lepri, G Lapadula, S Bonora, G Madeddu, F Maggiolo, A Antinori, M Galli, G Di Perri, P Viale, A d'Arminio Monforte, A Gori; ICONA Foundation Study Group. Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice.  PLoS One. 2016 Oct 7;11(10):e0160761. doi: 10.1371/journal.pone.0160761.
  2. N Squillace; P Lorenzini; G Lapadula; A Bandera; A Cozzi-Lepri; S Rusconi; M Puoti; A Castagna; A Antinori; A Gori; A d'Arminio Monforte. Triglycerides/HDL Ratio And Its Impact On Risk Of Diabetes Mellitus Development During Antiretroviral Therapy. J Antimicrob Chemother. 2016 Sep;71(9):2663-9. doi: 10.1093/jac/dkw185
  3. A Castagna, L Monno, S Carta, L Galli, S Carrara, V Fedele, G Punzi, I Fanti, P Caramello, AC LepriC, A De Luca, F Ceccherini-Silberstein, A d’Arminio Monforte; ICONA Foundation Study Group. Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression. Medicine (Baltimore). 2016 Nov;95(44):e5222.
  4. N Squillace, L Galli, A Bandera, A Castagna, G Madeddu, P Caramello, A Antinori, AM Cattelan, F Maggiolo, A Cingolani, A Gori, A d’Arminio Monforte, on behalf of the ICONA Foundation Study Group. High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects. Data from the ICONA Foundation Cohort. Medicine (Baltimore). 2016 Sep;95(36):e4434. doi: 10.1097/MD.0000000000004434.
  5. A d'Arminio Monforte, A Cozzi-Lepri, F Maggiolo, G Rizzardini, PE Manconi, N Gianotti, T Quirino, C Pinnetti, S Rusconi, A De Luca, A Antinori;Icona Foundation Study cohort. Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. PLoS One. 2016 Jun 27;11(6):e0156360. doi: 10.1371/journal.pone.0156360. eCollection 2016.
  6. A Di Biagio; A Cozzi-Lepri; R Prinapori; G Angarano; A Gori; T Quirino; A De Luca; A Costantini; C Mussini; G Rizzardini; A Castagna; A Antinori; A d'Arminio Monforte; for the ICONA Foundation Study Group. Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy.  JAIDS Journal of Acquired Immune Deficiency Syndromes: 1 March 2016 - Volume 71 - Issue 3 - p 263–271.
  7. A Saracino, P Lorenzini, S Lo Caputo, E Girardi, F Castelli, P Bonfanti, S Rusconi, P Caramello, N Abrescia, C Mussini, L Monno, A d’Arminio Monforte. Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort.  Clin Microbiol Infect. 2016 Mar;22(3):288.e1-8. doi: 10.1016/j.cmi.2015.10.026. Epub 2015 Nov 10.
2015
  1. C Mussini, P Lorenzini, M Puoti, M Lichtner, G Lapadula, S Di Giambenedetto, A Antinori, G Madeddu, A Cozzi-Lepri, A d’Arminio Monforte and A De Luca on behalf of the ICONA Foundation study group. Prognostic value of the fibrosis-4 index in human immunodeficiency virus type-1 infected patients initiating antiretroviral therapy with or without hepatitis C virus.  Plos ONE 2015 Dec 7;10(12):e0140877. doi: 10.1371/journal.pone.0140877. eCollection 2015
  2. A Bandera, A Gori, F Sabbatini, G Madeddu, S Bonora, R Libertone, C Mastroianni, P Bonfanti, A d'Arminio Monforte, A Cozzi-Lepri; Icona Foundation Study Group. Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. PLoS One. 2015 May 1;10(5):e0124252. doi: 10.1371/journal.pone.0124252. eCollection 2015.
  3. M Lichtner, P Cicconi, S Vita, A Cozzi-Lepri, M Galli, S Lo Caputo, A Saracino, A De Luca, MC Moioli, F Maggiolo, G Marchetti, V Vullo, A d'Arminio Monforte. Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients J Infect Dis. 2015 Jan 15;211(2):178-86. doi: 10.1093/infdis/jiu417. Epub 2014 Jul 31.
  4. A Cingolani, S Zona, E Girardi, ACozzi-Lepri, L Monno, E Quiros Roldan, G Guaraldi, A Antinori, A d'Arminio Monforte, S Marcotullio; Community-Oriented Study Group of the Icona Foundation Study Group. Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort.  HIV Med. 2015 May 11. doi: 10.1111/hiv.12226.
  5. C Mussini, P Lorenzini, A Cozzi-Lepri, G Lapadula, G Marchetti, E Nicastri, A Cingolani, M Lichtner, A Antinori, A Gori, A d’Arminio Monforte, for the Icona Foundation Study Group. CD4/CD8 ratio normalisation and non-AIDS related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. The Lancet HIV 2015; 2 (3): e98-e106
2014
  1. A Saracino, P Lorenzini, S Lo Caputo, E Girardi, F Castelli, P Bonfanti, M Galli, P Caramello, N Abrescia, C Mussini, L Monno, A d’Arminio Monforte. Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared tonatives: data from the ICONA cohort. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19769. doi: 10.7448/IAS.17.4.19769. eCollection 2014.
  2. A d'Arminio Monforte, L Galli, S Lo Caputo, M Lichtner, C Pinnetti, N Bobbio, D Francisci, A Costantini, A Cingolani, F Castelli, E Girardi and A Castagna for the ICONA Foundation Study Group. Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013. J Acquir Immune Defic Syndr 2014;67:258-267
  3. A Di Biagio, LA Nicolini, P Lorenzini, M Puoti, A Antinori A, A Cozzi-Lepri, A Gori, J Vecchiet, C Mussini, M Andreoni, C Viscoli, A d'Arminio Monforte, For The Icona Foundation Study Group. Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C co-infection: data from the ICONA Foundation cohort HIV Clinical Trials. HIV Clin Trials. 2014 Jul Aug;15(4):151-60. doi: 10.1310/hct1504-151
  4. G Rozera, I Abbate, E Giombini, A Castagna, A De Luca, F Ceccherini-Silberstein, A Cozzi Lepri, G Cassola, C Torti, A d'Arminio Monforte, G Ippolito and M R. Capobianchi on behalf of the ICONA Foundation Group. Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. J Antimicrob Chemother. 2014 Jul 10. doi:10.1093/jac/dku255. Epub 2014 Jul 10
  5. A d'Arminio Monforte, N Gianotti, A Cozzi-Lepri, C Pinnetti, M Andreoni, G di Perri, M Galli, A Poli, A Costantini, G Orofino, F Maggiolo, G Mazzarello, BM Celesia, F Luciani, ALazzarin, L Sighinolfi, G Rizzardini, P Bonfanti, CF Perno, A Antinori; ICONA Foundation Cohort. Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting. Antivir Ther. 2014;19(3):319-24. doi: 10.3851/IMP2687. Epub 2013 Sep 13
  6. G Marchetti, A Cozzi-Lepri, C Tincati, A Calcagno, F Ceccherini-Silberstein, A De Luca, A Antinori, A Castagna, M Puoti, A d'Arminio Monforte for Icona Foundation Study group Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study. BMC Infectious Diseases 2014, 14:79 doi:10.1186/1471-2334-14-79
  7. A Cingolani, A Cozzi-Lepri, A Ammassari, C Mussini, MA Ursitti, P Caramello, G Angarano, P Bonfanti, A De Luca, MS Mura, E Girardi, A Antinori, A d'Arminio Monforte, for Icona Foundation Study group. Timing of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohort. Plos One 2014; Feb 27;9(2):e89861
  8. G Meini, B Rossetti, C Bianco, F Ceccherini-Silberstein, S Di Giambenedetto, L Sighinolfi, L Monno, A Castagna, G Rozera, A d'Arminio Monforte, M Zazzi and A De Luca on behalf of the ICONA Foundation Group. Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. J Antimicrob Chemother. 2014 Mar;69(3):735-41
2013
  1. C Mussini, L Galli, A Cozzi-Lepri, A De Luca, A Antinori, V Tozzi, G Angarano, P Bonfanti, A Castagna and A d'Arminio Monforte for the ICONA Foundation Study Group. Incidence, time and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation cohort. J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):339-45
  2. M Bibas, A d'Arminio Monforte, A Antinori. Free Light Chains and the risk of nonmalignant AIDS events in HIV-infected patients treated with combination antiretroviral therapy. Clin Infect Dis. 2013 May;56(9):1349-50
  3. G Lapadula, A Cozzi-Lepri, G Marchetti, A Antinori, A Chiodera, E Nicastri, G Parruti, M Galli, A Gori, A d'Arminio Monforte; ICONA Foundation Study. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. AIDS. 2013 Mar 13;27(5):769-79
  4. V Cento, C Mirabelli, S Dimonte, R Salpini, Y Han, P Trimoulet, A Bertoli, V Micheli, G Gubertini, G Cappiello, A Spano, R Longo, M Bernassola, F Mazzotta, GM De Sanctis, XX Zhang, J Verheyen, A d'Arminio Monforte, F Ceccherini-Silberstein, CF Perno, V Svicher. Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution. J Gen Virol. 2013 Jan;94(Pt 1):143-9
  5. Alteri C, Artese A, Beheydt G, Santoro MM, Costa G, Parrotta L, Bertoli A, Gori C, Orchi N, Girardi E, Antinori A, Alcaro S, d'Arminio Monforte A, Theys K, Vandamme AM, Ceccherini-Silberstein F, Svicher V, Perno CF. Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. J Antimicrob Chemother. 2013 Oct;68(10):2205-9
2012
  1. M Bibas, P Lorenzini, A Cozzi-Lepri, A Calcagno, S di Giambenedetto, A Costantini, A Castagna, V Manfrin, A d'Arminio Monforte and A Antinori for the ICONA Cohort Study Group. Polyclonal serum free light chains elevation in HIV-infected patients. AIDS 2012, 23 October 2012; 16:2107-2110
  2. M Bibas, MP Trotta, A Cozzi-Lepri, P Lorenzini, C Pinnetti, G Rizzardini, G Angarano, P Caramello, L Sighinolfi, CM Mastroianni, G Mazzarello, A Di Caro, C Di Giacomo, A d'Arminio Monforte, and A Antinori; for the ICONA Foundation Study Group. Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. Am J Hematol. 2012 Aug;87(8):749-53
  3. A De Luca, K de Gaetano Donati, A Cozzi-Lepri, M Colafigli, A De Curtis, MR Capobianchi, A Antinori, A Giacometti, G Magnani, V Vullo, R Cauda, L Iacoviello, A d'Arminio Monforte, and The ICoNA Foundation Study Group. Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study. JAIDS 2012; 60 (3): e98-e101
  4. S Nozza, F Canducci, L Galli, A Cozzi-Lepri, MR Capobianchi, ER Ceresola, P Narciso, R Libertone, P Castelli, M Moioli, A d'Arminio Monforte, A Castagna; on behalf of the ICONA Foundation. Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naïve patients with high CD4 counts. J Antimicrob Chemother 2012 May;67(5):1224-1227
  5. E Girardi, P Scognamiglio, C Angeletti, A Gori, D Buonfrate, M Arlotti, G Mazzarello, A Castagna, M Andreoni, A d'Arminio Monforte, A Antinori and G Ippolito, for the I.Co.Na Foundation Study. Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis. BMC Health Services Research 2012, 12:38
  6. A Cingolani, A Cozzi-Lepri, A Castagna, D Goletti, A De Luca, P Scarpellini, I Fanti, A Antinori, A d'Arminio Monforte, and E Girardi. Impaired CD4 T-Cell Count Response to Combined Antiretroviral Therapy in Antiretroviral-Naive HIV-Infected Patients Presenting With Tuberculosis as AIDS-Defining Condition. Clin Infect Dis. 2012 Mar;54(6):853-61
2011
  1. F Vescini, A Cozzi-Lepri, M Borderi, MC Re, F Maggiolo, A De Luca, G Cassola, V Vullo, G Carosi, A Antinori, V Tozzi and A d'Arminio Monforte for the Icona Foundation Study Group. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):163-72
  2. A d'Arminio Monforte, A Cozzi-Lepri, E Girardi, A Castagna, C Mussini, S Di Giambenedetto, M Galli, G Cassola, V Vullo, E Quiros-Roldan, S Lo Caputo, A Antinori for the Icona Foundation Study Group. Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome. Antiviral Therapy 2011;16(7):1103-12
  3. C Torti, A d'Arminio Monforte, AL Pozniak, G Lapadula, G Cologni, A Antinori, A De Luca, C Mussini, A Castagna, P Cicconi, L Minoli, A Costantini, G Carosi, H Liang, BM Cesana; MASTER, Chelsea & Westminster, ICONA, Modena and S. Raffaele HIV Cohorts. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. BMC Infect Dis. 2011 Jan 25;11:23
  4. G Marchetti, A CozziI-Lepri, E Merlini, GM Bellistrì, A Castagna, M Galli, G Verucchi, A Antinori, A Costantini, A Giacometti, A Di Caro, and A d'Arminio Monforte for the Icona Foundation Study Group. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS 2011 Jul 17;25(11):1385-94
  5. F Tordato, A Cozzi-Lepri, P Cicconi, A De Luca, A Antinori, G Verucchi, A castagna, P Nasta, N ladisa, A Giacometti, A d'Arminio Monforte, and A Gori for the Icona Foundation Study Group. Evaluation of glomerular filtrationrate in HIV-1 infected patients before anf after combined antiretroviral therapy exposure. HIV Med. 2011 Jan;12(1):4-13
  6. MCF Prosperi, A Cozzi-Lepri, A Antinori, G Cassola, C Torti, G Magnani, G Pellizzer, A Giacometti, A d'Arminio Monforte and A De Luca for the Icona Foundation Study Group. Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008. HIV Med. 2011 Mar;12(3):174-82
  7. C Alteri, MM Santoro, I Abbate, G Rozera, A Bruselles, B Bartolini, C Gori, F Forbici, N Orchi, V Tozzi, G Palamara, A Antinori, P Narciso, E Girardi, V Svicher, F Ceccherini-Silberstein, MR Capobianchi, CF Perno 'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing. J Antimicrob Chemother. 2011 Nov;66(11):2615-23
2010
  1. MP Trotta, A Cozzi-Lepri, A Ammassari, J Vecchiet, G Cassola, P Caramello, V Vullo, F Soscia, A Chiodera, N Ladisa, C Abeli, R Cauda, AR Buonuomi, A Antinori, and A d'Arminio Monforte for the Icona Foundation Study Group. Rate of CD4+ Cell Count Increase Over Periods of Viral Load Suppression: Relationship with the Number of Previous Virological Failures. Clin Infect Dis. 2010, Aug 15; 51(4):456-464
  2. P Cicconi, A Cozzi-Lepri, A Castagna, EM Trecarichi, A Antinori, F Gatti, G Cassola, L Sighinolfi, P Castelli, A d'Arminio Monforte for the I.Co.N.A. Foundation Study Group. Insights into the reasons for discontinuation according to year of starting the first HAART in a cohort of antiretroviral naïve patients. HIV Medicine 2010, Feb;11(2):104-13
  3. M Zaccarelli, A Antinori, A Cozzi-Lepri, C Mussini, G Palamara, MM Santoro, V Spagnuolo, A d'Arminio Monforte, CF Perno, F Ceccherini-Silberstein. Is there any potential for first line Etravirine use? Analysis from a large dataset of ART-naïve HIV infected patients undergoing resistance test. J Acq Immune Def Syndr 2010, Jan 1;53(1):150-1
  4. MCF Prosperi, A Cozzi-Lepri, A Castagna, C Mussini, R Murri, A Giacometti, C Torti, A Costantini, P Narciso, F Ghinelli, A Antinori and A d'Arminio Monforte for the Icona Foundation Study Group. The incidence of malignancies in HIV-infected patients and postic role of current CD4 cell count: evidence from a Italian study. Clin Infect Dis. 2010 May 1;50(9):1316-21
  5. F Ceccherini-Silberstein, I Malet, L Fabeni, S Dimonte, V Svicher, R D'Arrigo, A Artese, G Costa, S Bono, S Alcaro, A d'Arminio Monforte, C Katlama, V Calvez, A Antinori, AG Marcelin, CF Perno Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J Antimicrob Chemother. 2010 Nov;65(11):2305-18
2009
  1. G Morsica, F Ancarani, S Bagaglio, M Maracci, P Cicconi, A Cozzi-Lepri, G Antonucci, R Bruno, T Santantonio, L Tacconi, F Baldelli, R Piscopo, D Santoro, A Lazzarin, A d'Arminio Monforte for the Hepa I.C.o.N.A and the Icona Study Groups. Occult Hepatitis B Virus Infection in a Cohort of HIV-Positive Patients: Correlation with Hepatitis C Virus Coinfection, Virological and Immunological Features. Infection 2009, 37(5):445-9
  2. A d'Arminio Monforte, A Cozzi-Lepri, A Castagna, A Antinori, A De Luca, C Mussini, S Lo Caputo, M Arlotti, G Magnani, G Pellizzer, F Maggiolo and M Puoti, for the ICONA Foundation Study Group. Risk of developing specific AIDS defining illnesses in HIV(/HCV co-infected patients with or without liver cirrhosis. Clin Infect Dis 2009, 49(4):612-22
  3. G Morsica, S Bagaglio, P Cicconi, MR. Capobianchi, G Pellizzer, P Caramello, A Orani, C Moioli, G Rizzardini, C Uberti-Foppa, M Puoti, A d'Arminio Monforte for the Hepa I.C.o.N.A and the Icona Foundation Study Groups. Viral Interference between Hepatitis B, C and D Viruses in Dual and Triple Infections in HIV Positive Patients. J Acq Immune Def Syndr 2009, 51:574-581.
2008
  1. B Zanone Poma, A Riva, M Nasi, P Cicconi, V Broggini, A Cozzi-Lepri, D Mologni, F Mazzotta, C Mussini, A d'Arminio Monforte, A Cossarizza, M Galli. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS 2008, 12;22(14):1769-78
  2. P Cicconi, A Cozzi-Lepri, G Orlando, A Matteelli, E Girardi, A Degli Esposti, C Moioli, G Rizzardini, A Chiodera, G Ballardini, A d'Arminio Monforte for the I.Co.N.A. Study Group. Recent acquired STD and the use of HAART in I.Co.N.A.: analysis of the incidence of acute hepatitis B and syphilis. Infection. 2008; 36(1):46-53
  3. MP Trotta, A Ammassari, R Murri, P Marconi, M Maccarelli, A Cozzi-Lepri, R Acinapura, N Abrescia, P De Longis, V Tozzi, A Scalzini, V Vullo, E Boumis, P Nasta, A d'Arminio Monforte, and A Antinori for the AdICoNA and AdeSpall Study Group. Self-Reported Sexual Dysfunction Is Frequent Among HIV-Infected Persons And Is Associated With Sub-Optimal Adherence To Antiretrovirals. AIDS Pat Care STD, 2008 Apr;22(4):291-9
  4. S de Wit, CA Sabin, R Weber, SW Worm, P Reiss, C Cazanave, W El-Sadr, A d´Arminio Monforte, E Fontas, MG Law, N Friis-Møller, JD Lundgren. Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study.  Diabetes Care. 2008 Jun;31(6):1224-9
2007
  1. M Bongiovanni, A Gori, A Cozzi-Lepri, A Antinori, A de Luca, G Pagano, A Chiodera, M Puoti, A d'Arminio Monforte for the ICONA Cohort. Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis? Clin Infect Dis. 2007 ;45(5):650-3
  2. F Ceccherini-Silberstein, V Svicher, T Sing, A Artese, MM Santoro, F Forbici, A Bertoli, S Alcaro, G Palamara, A d'Arminio Monforte, J Balzarini, A Antinori, T Lengauer, CF Perno. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. J Virol. 2007 Oct;81(20):11507-19
  3. B Larder, D Wang, A Revell, J Montaner, R Harrigan, F De Wolf, J Lange, S Wegner, L Ruiz, MJ Pérez-Elìas, S Emery, J Gatell, A d'Arminio Monforte, C Torti, M Zazzi and C Lane. The development of artificial neural networks to predict virological response to combination HIV therapy. Antiviral Therapy 2007; 12:15-24
  4. MP Trotta, A Ammassari, R Murri, A d'Arminio Monforte, A Antinori. Sexual dysfunction in HIV infection. Lancet 2007;369(9565):905-6
  5. P Cicconi, A Cozzi-Lepri, A Phillips, M Puoti, G Antonucci, PE Manconi, G Tositti, V Colangeli, M Lichtner, A d'Arminio Monforte for the HepaI.Co.N.A. and I.Co.N.A. Study Groups. Is the raised risk of liver enzyme elevation in hepatitis co-infected patients any greater in those on antiretroviral therapy than in naïve patients? AIDS 2007; 21(5):599-606
2006
  1. A Cozzi-Lepri, A De Luca, AN Phillips, M Bongiovanni, S Di Giambenedetto, M Mena, MC Moioli, M Arlotti, L Sighinolfi, P Narciso, M Lichtner, R Cauda, A d'Arminio Monforte; ICoNA Study Group; UCSC-Roma HIV Cohort Study Group; IMIT Study Group. A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads. J Infect Dis 2006;194(1):20-8
  2. A De Luca, A Cozzi-Lepri, A Antinori, M Zaccarelli, M Bongiovanni, S Di Giambenedetto, P Marconi, P Cicconi, F Resta, B Grisorio, M Ciardi, A d'Arminio Monforte. Lopinavir/ritonavir or efavirenz plus two nucleosides analogues as first-line antiretroviral therapy: a non-randomized comparison. Antiviral Therapy 2006;11(5):609-618
  3. M Puoti, A Cozzi-Lepri, F Castelli, G Paraninfo, N Friis Moller, J D Lundgren, B Ledergerber, M Rickenbach, I Suarez-Lozano, M Garrido, F Dabis, M Winnock, L Milazzo, A Gervais, F Raffi, J Gill, J Rockstroh, N Qurishi, C Mussini, A Castagna, A De Luca, A d'Arminio Monforte for the HBV-HIV international intercohort study group. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis Antiviral Therapy 2006; 11 567-574
  4. M Solmone, E Girardi, El Lalle, I Abbate, A d'Arminio Monforte, A Cozzi-Lepri, A Alessandrini, R Piscopo, F Ebo, L Cosco, G Antonucci, G Ippolito, MR Capobianchi for the HepaI.Co.N.A. and the I.Co.N.A. Study Group. Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCVcoinfected patients according to the pattern of response to highly active antiretroviral therapy. Antiviral Therapy 2006; 11: 87-94
  5. V Svicher, T Sing A d'Arminio Monforte, A Antinori, T Lengauer,F Ceccherini-Silberstein, CF Perno. Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol 2006: 80 (14):7186-7198
  6. R Murri, A Cozzi-Lepri, P Cicconi, A Poggio, M Arlotti, G Tositti, D Santoro, ML Soranzo, G Rizzardini, V Colangeli, M Montroni, A d'Arminio Monforte; ICoNA Study Group. Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naïve patients study. J Acquir Immune Defic Syndr. 2006;41(1):23-30
  7. P Biswas, A Cozzi-Lepri, F Delfanti, A Galli, V Colangeli, MC Moioli, A Scarchilli, N Abrescia, G Vigevani, A d'Arminio Monforte, R Novati, A Lazzarin. Significant link between sCD30 changes and HIV viremia in patients treated with HAART. J Med Virol. 2006;78(12):1513-1519
  8. V Svicher, T Sing, MM Santoro, A Bertoli, F Forbici, A Artese, A d'Arminio Monforte, A Antinori, CF Perno and F Ceccherini-Silberstein Additional mutations in HIV-1 reverse transcriptase involved in regulation of NNRTI resistance. Antiviral Therapy, 2006 11:S165
2005
  1. G Antonucci, E Girardi, A Cozzi-Lepri, MR Capobianchi, G Morsica, P Pizzaferri, N Ladisa, L Sighinolfi, A Chiodera, M Solmone, E Lalle, G Ippolito, A d'Arminio Monforte for the HepaI.Co.N.A., and the I.Co.N.A. Study Group. Response to HAART and GB virus type C coinfection in a cohort of antiretroviral naïve HIV-infected individuals. Antiviral Therapy 2005, 10:109-117
  2. A d'Arminio Monforte, A Cozzi-Lepri, A Phillips, A De Luca, R Murri, C Mussini, P Grossi, A Galli, G Ballardini, M Montoni, P Tundo, M Moroni for the I.Co.N.A Study Group. Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the I.Co.N.A study. J Acquir Immune Defic Syndr 2005; 38:407-416
  3. V Svicher, F Ceccherini-Silberstein, F Erba, M Santoro, C Gori, MC Bellocchi, S Giannella, MP Trotta, A d'Arminio Monforte, A Antinori, and CF Perno. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. J Antimicrob Agents Chemother 2005; 49:2015-2025
  4. CF Perno, A Cozzi-Lepri, F Ceccherini-Silberstein, A d'Arminio Monforte, for ICONA Study Group. Correlation between M36I in HIV protease and selection/maintenance of L90M after treatment with protease inhibitors. J Infect Dis 2005; 191:1779-80
  5. G Antonucci, E Girardi, A Cozzi-Lepri, MR Capobianchi, A De Luca, M Puoti, E Petrelli, G Carnevale, G Rizzardini, PA Grossi, P Viganò, MC Moioli, F Carletti, M Solmone, G Ippolito, A d'Arminio Monforte for the HepaI.Co.N.A., and the I.Co.N.A. Study Group. Role of HCV viraemia and HCV genotype in the immune recovery from HAART in a cohort of antiretroviral naïve HIV-infected individuals. Clin Infect Dis 2005; 40:e101-109
  6. MS Aloisi, R Murri, A d'Arminio Monforte, D Bertelli, V Colangeli, F Leoncini, G Ippolito, E Girardi. for the I.CO.N.A. Study Group. Partnership of HIV-infected women and health status. J Acquir Immune Defic Syndr 2005; 39(4):502-503
  7. M Merito, A Bonaccorsi, F Pammolli, M Riccaboni, G Baio, C Arici, A d'Arminio Monforte, P Pezzotti, D Corsini, A Tramarin, R Cauda, V Colangeli, G Pastore. Economic evaluation of HIV treatments: the I.CO.N.A. cohort study. Health policy 2005; 74(3):304-313
  8. G Antonucci, A Cozzi-Lepri, E Girardi, MR Capobianchi, A De Luca, A d'Arminio Monforte for the HepaI.Co.N.A. Study Group. Effect of HCV genotype on CD4+ cell count in a cohort of antiretroviral naïve HIV-infected individuals. J Infect Dis 2005; 192(4):703-704
  9. F Ceccherini-Silberstein, F Gago, M Santoro, C Gori, V Svicher, F Rodriguez-Barrios, R d'Arrigo, M Ciccozzi, A Bertoli, A d'Arminio Monforte, J Balzarini, A Antinori and CF Perno for the I.CO.N.A. Study Group. High sequence conservation of HIV-1 reverse transcriptase under drug pressure despite a continuous appearance of mutations. J Virol 2005; 79:10718-10729
  10. F Ceccherini-Silberstein, V Svicher, T Sing, M Santoro, N Beerenwikel, F Gago, A Bertoli, F Forbici, MC Bellocchi, P Narciso, A d'Arminio Monforte, A Antinori and CF Perno for the I.CO.N.A. Study Group Involvement of novel HIV-1 reverse transcriptase mutations in the highly ordered regulation of NRTI resistance. Antiviral Therapy 2005; 10:S106
2004
  1. M Violin, A Cozzi-Lepri, R Velleca, A Vincenti, S D'Elia, F Chiodo, F Ghinelli, A Bertoli, A d'Arminio Monforte, CF Perno, M Moroni, C Balotta for the I.CO.N.A. Study Group. Risk of virological failure in antiretroviral-naïve patients with HIV-1 revertants at RT position 215 starting thymidine analog-containing HAART: a cohort study. AIDS 2004; 18(2):227-235
  2. A Antinori, A Cozzi-Lepri, A Ammassari, MP Trotta, D Nauwelaers, R Murri, S Melzi, P Narciso, P Nasta, M Zaccarelli, P Santopadre, J Vecchiet, CM Izzo and A d'Arminio Monforte for the Ad.I.Co.N.A. Study Group. Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antiviral Therapy 2004; 9:291-294
  3. CF Perno, A Cozzi-Lepri, F Forbici, A Bertoli, M Violin, MS Mura, GP Cadeo, A Orani, A Chirianni, C De Stefano, C Balotta, A d'Arminio Monforte for the I.CO.N.A Study Group. Minor Mutations in HIV-Protease at Baseline and Appearance of Primary Mutation 90M in Patients Failing Their First Protease-Inhibitor Antiretroviral Regimens. J Infect Dis 2004; 189(11):1983-7
  4. F Ceccherini-Silberstein, F Erba, F Gago, A Bertoli, F Forbici, MC Bellocchi, C Gori, R d'Arrigo, L Marcon, C Balotta, A Antinori, A d'Arminio Monforte, and Carlo-Federico Perno for the I.CO.N.A. Study Group. Identification of the Minimal Conserved Structure of HIV-1. Protease in the Presence and Absence of Drug Pressure. AIDS 2004; 18(12):F11-9
  5. E Girardi, MS Aloisi, C Arici, P Pezzotti, D Serraino, R Balzano, GM Vigevani, F Alberici, M Ursitti, M D'Alessandro, A d'Arminio Monforte, G Ippolito for the I.CO.N.A. Study Group. Delayed presentation and late testing for HIV: demographic and behavioural risk factors in a multicenter study in Italy. J Acquir Immune Defic Syndr 2004; 36:951-959
  6. A De Luca, A Cozzi-Lepri, CF Perno, C Balotta, S Di Giambenedetto, A Poggio, G Pagano, G Tositti, R Piscopo, A Del Forno, F Chiodo, G Magnani and A d'Arminio Monforte for the I.Co.N.A drug resistance study group and the I.Co.N.A study group. Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems. Antiviral Therapy 2004; 9: 743-752
  7. M Puoti, A Cozzi-Lepri, F Ancarani, R Bruno, S Ambu, T Ferraro, P Tundo, T Santantonio, M Toti, M Bonasso, A d'Arminio Monforte for the HepaI.Co.N.A. Study Group. The management of hepatitis B virus (HBV) / HIV-1 co-infected patients starting their first HAART regimen. Treating two infections at the price of one drug? Antiviral Therapy 2004; 9:811-817
  8. A Ammassari, A Antinori, MS Aloisi, MP Trotta, R Murri, L Bartoli, A d'Arminio Monforte, AW Wu, F Starace. The relationship of depressive symptoms, neurocognitive impairment and HAART adherence among HIV-infected persons. Psychosomatics 2004; 45: 394-402
  9. R Murri, A Ammassari, MP Trotta, A De Luca, S Melzi, C Minardi, M Zaccarelli, P Rellecati, P Santopadre, F Soscia, A Scasso, V Tozzi, M Ciardi, GC Orofino, P Noto, A d'Arminio Monforte, A Antinori, AW Wu for the AdICoNA Study Group. Patient-reported and physician estimated adherence to HAART: social and clinic center related factors are associated with discordance. J Gen Intern Med 2004; 19: 1104-1110
  10. M Violin, R Velleca, A Cozzi-Lepri, C Riva, PA Grossi, G Carnevale, G Rizzardini, E Petrelli, CF Perno, A d'Arminio Monforte, C Balotta. Prevalence of HIV-1 primary drug resistance in seroconverters of I.CO.N.A. cohort over the period 1996-2001. J Acquir Immune Defic Syndr 2004; 36 (2): 761-764
2003
  1. MP Trotta, A Ammassari, A Cozzi-Lepri, M Zaccarelli, F Castelli, P Narciso, S Melzi, R Murri, F Baldelli, P Noto, J Vecchiet, A De Luca, A d'Arminio Monforte and A Antinori for the AdICONA and AdeSpall Study Group. Adherence to HAART is better in patients receiving NNRTI-containing regimens than in those receiving PI-containing regimens. AIDS 2003; 17:1099-1102.
  2. E Riva, G Antonelli, C Scagnolari, M Pistello, MR Capobianchi, A d'Arminio Monforte, P Pezzotti, F Dianzani for the I.CO.N.A Study Group. Human Immunodeficiency Virus (HIV) DNA Load and Level of Immunosuppression in Treatment-Naive HIV-1-Infected Patients. J Infect Dis 2003; 187:1826-1827
  3. G Nasti, R Talamini, A Antinori, F Martellotta, G Jacchetti, F Chiodo, G Ballardini, L Stoppini, G Di Perri, M Mena, M Tavio, E Vaccher, A d'Arminio Monforte and U Tirelli for GICAT and ICONA Study Groups. AIDS-related Kaposi's sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS clinical trial group staging system in the HAART era. J Clin Oncol 2003; 21:2876-2882
  4. R Murri, A Cozzi-Lepri, AN Phillips, E Girardi, G Nasti, S Ferrara, MS Mura, C Mussini, E Petrelli, M Arlotti, C De Stefano, P Vigano, R Novati, A Cargnel, A d'Arminio Monforte for the I.CO.N.A. Study Group. Access to antiretroviral treatment, incidence of sustained therapy interruptions and risk of clinical events according to sex: evidence from the I.CO.N.A study. J Acquir Immune Defic Syndr 2003; 34:184-191
  5. A Ammassari, F Starace, MS Aloisi, MP Trotta, R Murri, A d'Arminio Monforte, A Antinori. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology 2003; 61:723-724
  6. G Nasti, F Martellotta, M Berretta, M Mena, M Fasan, G Di Perri, R Talamini, G Pagano, M Montroni, R Cinelli, E Vaccher, A d'Arminio Monforte, U Tirelli. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 2003; 11:2440-2446
2002
  1. A Cozzi-Lepri, AN Phillips, A d'Arminio Monforte, N Piersantelli, A Orani, N Petrosillo, F Leoncini, T Ferraro, P Grima, N Abrescia and M Moroni for the I.CO.N.A. study group. Virological and immunological response to regimens containing nevirapine or efavirenz in combination with two nucleoside analogues in the I.CO.N.A. Study. J Infect Dis 2002; 185: 1062-1069
  2. CF Perno, A Cozzi-Lepri, C Balotta, M Violin, A Bertoli, L Monno, T Zauli, M Montroni, G Ippolito, A d'Arminio Monforte, for the I.CO.N.A. Study Group. Low prevalence of primary mutations associated to drug resitance in antiretroviral-naïve patients at initiation of HAART. AIDS 2002; 16:619-624
  3. M Violin, F Forbici, A Cozzi-Lepri, R Velleca, A Bertoli, PE Manconi, A Lazzarin, S Pasquinucci, L Tacconi, G Carnevale, F Mazzotta, L Bonazzi, M Montroni, A Chirianni, MR Capobianchi, G Ippolito, M Moroni, CF Perno, A d'Arminio Monforte, C Balotta for the I.CO.N.A. Study Group. Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naive for Antiretrovirals. J Biol Regulat Homeost Agents 2002; 16: 37-43
  4. F Starace, L Bartoli, MS Aloisi, A Antinori, P Narciso, G Ippolito, L Ravasio, MC Moioli, D Vangi, L Gennero, O Coronado, A Giacometti, S Nappa, ML Perulli, V Montesarchio, A La Gala, F Ricci, L Cristiano, M De Marco, CM Izzo, P Pezzotti and A d'Arminio Monforte for the NeuroI.Co.N.A. Study Group. Cognitive and affective disorders associated to HIV infection in the HAART era. Findings from the NeuroICONA Study. Acta Psych Scand 2002; 106: 20-26
  5. A De Luca, R Bugarini, A Cozzi-Lepri, M Puoti, E Girardi, A Antinori, A Poggio, G Pagano G Tositti, GP Cadeo, A Macor, M Toti and A d'Arminio Monforte for the I.CO.N.A. Study Group. Coinfection with hepatitis viruses and outcome of the first antiretroviral regimen in previously naïve HIV-infected subjects. Arch Intern Med 2002; 162: 2125-2132
  6. M Galli, A Cozzi-Lepri, AL Ridolfo, C Gervasoni, L Ravasio, L Corsico, E Gianelli, M Vaccarezza, V Vullo, A Cargnel, L Minoli, O Coronado, A Giacometti, A Antinori, G Antonucci, A d'Arminio Monforte, M Moroni for the LipoICoNa study. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LIPOICONA study. Arch Intern Med 2002; 162:2621-2628
  7. MS Aloisi, C Arici, R Balzano, P Noto, R Piscopo, G Filice, F Menichetti, A d'Arminio Monforte, G Ippolito, E Girardi for the I.Co.N.A. Behavioural Epidemiology Study Group. Behavioural correlates of adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31(3):S145-S148
  8. A Ammassari, A Antinori, A Cozzi-Lepri, MP Trotta, G Nasti, AL Ridolfo, F Mazzotta, AW Wu, A d'Arminio Monforte, M Galli for the AdI.Co.N.A. and the LipoI.Co.N.A. Study Groups. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 2002; 31(3):S140-S144
  9. A Ammassari, MP Trotta, R Murri, F Castelli, P Narciso, P Noto, J Vecchiet, A d'Arminio Monforte, AW Wu, A Antinori for the AdICONA Study Group. Correlates and predictors of adherence to HAART: overview of published literature. J Acquir Immune Defic Syndr 2002; 31(3):S123-S127
  10. R Murri, A Antinori, A Ammassari, S Nappa, G Orofino, N Abrescia, C Mussini, A d'Arminio Monforte, AW Wu for the AdICoNA Study Group. Physician estimates of adherence and the patient-physician relationship as a setting to improve adherence to antiretrovirals. J Acquir Immune Defic Syndr 2002; 31(3):S158-S162
  11. CF Perno, F Ceccherini-Silberstein, A De Luca, A Cozzi-Lepri, C Gori, A Cingolani, MC Bellocchi, MP Trotta, P Piano, F Forbici, A Scasso, V Vullo, A d'Arminio Monforte, A Antinori, for the AdICoNA Study Group. Virologic correlates of adherence to antiretroviral medications and therapeutic failure. J Acquir Immune Defic Syndr 2002; 31(3):S118-S122
  12. F Starace, A Ammassari, MP Trotta, R Murri, P De Longis, C Izzo, A Scalzini, A d'Arminio Monforte, AW Wu, A Antinori. Depression is a risk factor for sub-optimal adherence to HAART. J Acquir Immune Defic Synd 2002; 31(3):S136-S139
  13. MP Trotta, A Ammassari, S Melzi, M Zaccarelli, N Ladisa, L Sighinolfi, MS Mura, A d'Arminio Monforte and A Antinori for the AdICoNA Study Group. Treatment related factors and HAART adherence. J Acquir Immune Defic Synd 2002; 31(3):S128-S131
  14. M Guarinieri for the I.CO.N.A. Community Advisory Board. Highly Active Antiretroviral Therapy: the patient's point of view. J Acquir Immune Defic Synd 2002; 31(3):S167-S169
2001
  1. E Girardi, MS Aloisi, D Serraino, M Carballo, A d'Arminio Monforte, G Rezza, M Moroni, GP Carosi, A Alessandrini, D Giacobbi, L Cremonini, S Ranieri, M Montroni, G Ippolito for the I.CO.N.A. Study Group. Sexual behaviour of heterosexual individuals with HIV infection naïve for antiretroviral therapy in Italy. Sex Transm Infect 2001; 77:130-134
  2. B Ledergerber, A Mocroft, P Reiss, H Furrer, O Kirk, M Bickel, C Uberti-Foppa, C Pradier, A d'Arminio Monforte, MME Schneider, and JD Lundgren, for eight European HIV Cohorts. Discontinuation of Secondary Prophylaxis against Pneumocystis carinii Pneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy. N Engl J Med 2001; 344 (3):168-174
  3. A Cozzi-Lepri, AN Phillips, A d'Arminio Monforte, F Castelli, A Antinori, A De Luca, P Pezzotti, F Alberici, A Cargnel, P Grima, R Piscopo, T Prestileo, G Scalise, M Vigevani and M Moroni for the I.CO.N.A. Study Group. When to start highly active antiretroviral therapy in chronically HIV infected patients: evidence from the I.CO.N.A. Study. AIDS 2001; 15:983-990
  4. C Balotta, G Facchi, M Violin, S Van Dooren, A Cozzi-Lepri, F Forbici, A Bertoli, D Senese, P Caramello, G Carnevale, G Rizzardini, L Cremonini, L Monno, G Rezza, CF Perno, G Ippolito, A d'Arminio Monforte, AM Vandamme, M Moroni for the I.CO.N.A. Study Group. Increasing prevalence of non-clade B HIV-1 strains in heterosexuals, as monitored by the analysis of the RT and protease sequences. J Acquir Immune Defic Syndr 2001; 27:499-505
  5. M Dorrucci, P Pezzotti, B Grisorio, C Minardi, MS Mura, V Vullo, A d'Arminio Monforte, for the I.CO.N.A. Study Group. Time to discontinuation of the first HAART regimen: a comparison between PI- and NNRTI-containing regimens. AIDS 2001; 15:1733-1736
  6. CF Perno, A d'Arminio Monforte, C Balotta, A Cozzi-Lepri, F Forbici, M Violin, A Bertoli, G Facchi, P Pezzotti, GP Cadeo, G Tositti, S Pasquinucci, S Pauluzzi, A Scalzini, B Salassa, A Vincenti, AN Phillips, F Dianzani, A Appice, G Angarano, L Monno, G Ippolito, M Moroni for the I.CO.N.A. Study Group. Secondary mutations in the protease region are predictors of virological failure in antiretroviral-naïve patients treated with protease inhibitors-containing HAART regimens. J Infect Dis 2001; 184: 983-991
  7. A d'Arminio Monforte, R Bugarini, P Pezzotti, A De Luca, A Antinori, C Mussini, F Milazzo, U Tirelli, R Bruno, F Gritti, M Piazza, S Chigiotti, A Chirianni, C De Stefano, E Pizzigallo, O Perrella, and M Moroni, for the I.CO.N.A. Study Group. Low frequency of severe hepatic cytolysis and strong association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001; 28(2):114-123
  8. CF Perno, A Cozzi-Lepri, C Balotta, F Forbici, M Violin, A Bertoli, G Facchi, P Pezzotti, G Angarano, C Arici, P Narciso, A Orani, E Raise, A Scalzini, A Poggio, G Ippolito, M Moroni, A d'Arminio Monforte and the ICONA Study Group. Impact of mutations conferring reduced susceptibility to lamivudine (3TC) on the response to antiretroviral therapy. Antiviral Therapy 2001; 6 (3):195-198
  9. A Ammassari, R Murri, P Pezzotti, MP Trotta, L Ravasio, P De Longis, S Lo Caputo, P Narciso, S Pauluzzi, G Carosi, S Nappa, P Piano, CM Izzo, M Lichtner, G Rezza, G Ippolito, A d'Arminio Monforte, AW Wu, A Antinori for the AdICONA Study Group. Self-reported symptoms and medication side effects influence adherence to HAART in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28:445-449
  10. E Girardi, C Arici, M Ferrara, D Ripamonti, MS Aloisi, A Alessandrini, A Scalzini, A d'Arminio Monforte, D Serraino, and G Ippolito, for the I.CO.N.A. Behavioural Epidemiology Study. Estimating duration of HIV infection with CD4 count and HIV-1 RNA at presentation. AIDS 2001; 15: 2201-2203
2000
  1. A d'Arminio Monforte, A Cozzi-Lepri, G Rezza, P Pezzotti, A Antinori, AN Phillips, G Angarano, V Colangeli, A De Luca, G Ippolito, L Caggese, F Soscia, G Filice, F Gritti, P Narciso, U Tirelli, M Moroni for the I.CO.N.A. Study Group. Insights into the reasons for discontinuation of the first highly active antiretrovial therapy (HAART) regimen in a cohort of antiretroviral naïve patients. AIDS 2000; 14:499-507
  2. G Rezza, A Cozzi-Lepri, A d'Arminio Monforte, P Pezzotti, F Castelli, F Dianzani, A Lazzarin, A De Luca, M Arlotti, F Leoncini, PE Manconi, F Milazzo, L Minoli, A Poggio, G Ippolito, A N Phillips, M Moroni for the I.CO.N.A. Study Group. Plasma viral load concentrations in women and men from different exposure categories and known duration of HIV infection. J Acquir Immune Defic Syndr 2000; 25:56-62
  3. MS Aloisi, D Serraino, E Girardi, A d'Arminio Monforte, A Cargnel, L Bonazzi, N Petrosillo, N Abrescia, F Mazzotta, V Vullo, T Ferraro, F Suter, G Rezza, G Ippolito for the I.CO.N.A. Study Group. Sexual behaviour of women living with HIV/AIDS naïve for antiretroviral therapy: the ICONA-BEHEPI Study. AIDS Care 2000; 12 (6): 789-795
  4. P Pezzotti, A d'Arminio Monforte, R Bugarini, G Rezza, C Arici, G Angarano, C Fiorini, F Alberici, O Armignacco, F Menichetti, T Prestileo, L Sighinolfi, A Sinicco, F Resta, M Vigevani, G Ippolito, for the I.CO.N.A. Study Group. Antiretroviral therapy in HIV-infected individuals in clinical practice: are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic parameters? Eur J Epidem 2000; 16(10):219-226
1999
  1. M Moroni on the behalf of I.CO.N.A. Study Group. Sex differences in HIV-1 viral load and progression to AIDS. The Lancet 1999; 353:589-590

Amici di ICONA

Gilead MSD ViiV
| Privacy policy | Cookies policy | Termini e condizioni di utilizzo |
© Effetti srl
P. IVA 10756900154
Ultimo aggiornamento: 06.10.2023

icona